Study Finds Suicidal Thoughts May Persist after Depression Remission

June 6, 2022 13:29:06

A new study has found that more than 30% of individuals in remission from major depressive disorder usually continue experiencing suicidal symptoms, even after the most severe stage of the illness has passed.

Major depressive disorder accounts for between 60% and 86% of all suicides. The disorder waxes and wanes, with roughly 80% of patients with the disease experiencing no less than five recurrences. Symptoms of suicide may sometimes re-appear, but they don’t always result in action.

Despite the close relation between suicidal behavior and thoughts and the disorder, not many studies have looked into suicidal symptoms in connection with remissive and recurrent major depressive disorder. The researchers’ objective was to study the presence of suicidal symptoms in individuals with recurrent depression and find out if symptoms of suicide were associated with depression’s recurrence.

For their research, the scientists recruited 73 patients with major depressive disorder and 45 controls. They then assessed for symptoms of suicide in every one of them and utilized a cohort design in monitoring recurrences every four or so months over a 2.5-year period.

The scientists discovered that during remission, participants with major depressive disorder self-reported experiencing higher depressive symptom levels in comparison to the control group. They also found that self-reported symptoms of suicide were higher in this group in comparison to the controls at 28% vs. 2.2%.

In addition to this, they discovered that higher levels of suicide symptoms were linked to higher symptoms of depression over the stipulated period, noting that during the entire period of the study, no participant used antidepressants to manage their symptoms. The researchers stated in their report that while depression predicted suicidal thoughts, it didn’t forecast suicidal behavior, noting that the majority of depressed individuals didn’t take part in suicidal behaviors.

In their report, the group also noted that while it recruited a particular cohort with remittent, recurrent symptoms, the study could be restricted by assessment. Instead of using a suicide ideation scale, the researchers used a depression scale. This may have skewed the findings and made it difficult for them to determine whether the rating related to suicidal or depression thoughts.

The researchers hope that these discoveries will help healthcare providers to better characterize patients with major depressive disorder who may be at risk of recurrence. They recommend that suicidal symptoms be monitored closely during remission and look out for any signs of impending relapse.

The researchers published their findings in “Psychiatric Research.”

There is plenty of ongoing R&D being done by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) aimed at finding breakthrough psychedelic medicines, which will mark a new chapter in the way mental health issues are treated. These treatments are urgently needed given the spike in these conditions due to the COVID-19 pandemic.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.